natgillin/translations-raw huggingface dataset:
• Changes in the recording of electrical changes (ECG) in the heart which correspond to heart rhythm disturbances
• spremembe zapisa elektrokardiograma (EKG), ki kažejo na motnje srčnega ritma
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
PRILOGA II A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Preobčutljivost na učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
• Increased appetite
• zvečanje apetita
In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day.
V kliničnem preskušanju za oceno vpliva pregabalina na motiliteto sperme, so bili zdravi moški izpostavljeni pregabalinu v odmerku 600 mg/dan.
• Difficulty with writing properly
• težave s pisanjem
Pregabalin and lamotrigine were similarly safe and well tolerated.
Pregabalin in lamotrigin sta si bila podobna glede varnosti in bolniki so ju enako dobro prenašali.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data)).
V spodnji preglednici 2 so po organskih sistemih in pogostnosti navedeni vsi neželeni učinki, ki so se pojavili pri več kot enem bolniku in z incidenco, večjo kot pri placebu (zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)).
Women of childbearing potential/Contraception in males and females As the potential risk for humans is unknown, effective contraception must be used in women of child bearing potential.
Ženske v rodni dobi/Kontracepcija pri moških in ženskah Ker možno tveganje za ljudi ni znano, je pri ženskah v rodnem obdobju potrebna uporaba učinkovite kontracepcije.
• Painful menstrual periods
• boleče menstruacije
In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 l/kg.
Pri človeku je navidezni volumen porazdelitve pregabalina po peroralni uporabi približno 0,56 l/kg.
Pregabalin pharmacokinetics in patients younger than 3 months old have not been studied (see sections 4.2, 4.8 and 5.1).
Farmakokinetike pregabalina niso preučevali pri bolnikih, mlajših od 3 mesecev (glejte poglavja 4.2, 4.8 in 5.1).
Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.
Kaže, da pregabalin aditivno prispeva k okvari kognitivnega in grobega motoričnega delovanja, ki jo povzroča oksikodon.
Inter-subject pharmacokinetic variability for pregabalin is low (<20%).
Razlike v farmakokinetiki pregabalina od posameznika do posameznika so majhne (< 20 %).
Pregabalin is not bound to plasma proteins.
Pregabalin ni vezan na beljakovine v plazmi.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.
Bolnikom (in skrbnikom bolnikov) je treba svetovati, naj poiščejo zdravniško pomoč, če se pojavijo znaki samomorilnega razmišljanja in vedenja.
A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prekinitvijo zdravljenja s pregabalinom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
GSP Proizvodi d.o.o.
SlovenijaGSP Proizvodi d.o.o.
Epilepsy or Generalised Anxiety Disorder:
Epilepsija ali generalizirana anksiozna motnja:
Mylan Hungary Kft Mylan utca 1, Komárom, 2900, Hungary
Mylan Hungary Kft Mylan utca 1, Komárom, 2900, Madžarska
Pregabalin Mylan Pharma is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.
Zdravilo Pregabalin Mylan Pharma ni namenjeno temu, da bi ga jemali samo, temveč ga je vedno treba uporabljati v kombinaciji z drugimi zdravili proti epilepsiji.
Pregabalin Cmax and AUC parameters increased in a linear manner with increasing dose within each age group.
Parametra Cmax in AUC za pregabalin sta se v vseh starostnih skupinah večala linearno z večanjem odmerka.
If your treatment is stopped it should be done gradually over a minimum of 1 week.
V tem primeru boste zdravilo opustili postopoma v teku najmanj enega tedna.
Pregabalin terminal half-life averaged about 3 to 4 hours in paediatric patients up to 6 years of age, and 4 to 6 hours in those 7 years of age and older.
Končni razpolovni čas pregabalina je bil v povprečju približno 3 do 4 ure pri pediatričnih bolnikih, starih do 6 let, ter od 4 do 6 ur pri 7-letnikih in starejših.
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to approximately 2.5 hours.
Hitrost absorpcije pregabalina se zmanjša, če je uporabljen s hrano; Cmax se zmanjša za približno 25-30 % in tmax se podaljša na približno 2,5 ure.
• Coldness of hands and feet
• hladne dlani in stopala
Each hard capsule contains either 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg or 300 mg of pregabalin.
Ena trda kapsula vsebuje 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg ali 300 mg pregabalina.
Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin.
Po odmerku radioaktivno označenega pregabalina je šlo približno 98 % v urinu izločene radioaktivnosti na račun nespremenjenega pregabalina.
Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered.
Zato je treba bolnike med zdravljenjem nadzirati glede znakov samomorilnega razmišljanja in vedenja ter razmisliti o ustreznem zdravljenju.
Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.
Kar zadeva prekinitev dolgotrajnega zdravljenja s pregabalinom, podatki kažejo, da sta incidenca in resnost odtegnitvenih simptomov lahko odvisni od odmerka.
• Muscle damage
• mišične poškodbe
Two-year carcinogenicity studies with pregabalin were conducted in rats and mice.
Dvoletna študija kancerogenosti s pregabalinom je bila narejena na miših in podganah.
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano dne: .
The AUC was lower by 30% in paediatric patients below a weight of 30 kg due to an increased body weight adjusted clearance of 43% for these patients in comparison to patients weighing ≥30 kg.
Vrednost AUC je bila pri pediatričnih bolnikih, lažjih od 30 kg, za 30 % nižja zaradi povečanega očistka, prilagojenega telesni masi, ki je bil pri teh bolnikih 43 % v primerjavi z bolniki s telesno maso 30 kg ali več.
Discontinuation of pregabalin may result in resolution or improvement of these visual symptoms.
Prenehanje uporabe pregabalina lahko povzroči izboljšanje ali izginotje teh simptomov.
The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)5- methylhexanoic acid].
Učinkovina pregabalin je analog gama-aminomaslene kisline (S)-3-(aminometil)-5-metilheksanojska kislina].
If you have the impression that the effect of Pregabalin Mylan Pharma is too strong or too weak, talk to your doctor or pharmacist.
Če imate občutek, da je učinek zdravila Pregabalin Mylan Pharma premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
When pregabalin and opioids will be used in combination, measures to prevent constipation may be considered (especially in female patients and elderly).
Ob sočasni uporabi pregabalina in opioidov je potrebno razmisliti o ukrepih za preprečevanje zaprtja (predvsem pri ženskah in starejših bolnikih).
In accordance with current clinical practice, if pregabalin has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and 4.8).
Če je treba uporabo pregabalina prekiniti, ga je skladno s trenutno klinično prakso, ne glede na indikacijo, priporočljivo zmanjševati postopoma vsaj 1 teden (glejte poglavji 4.4 in 4.8).
If you take more Pregabalin Mylan Pharma than you should Call your doctor or go to the nearest hospital emergency unit immediately.
Če ste vzeli večji odmerek zdravila Pregabalin Mylan Pharma, kot bi smeli Pokličite zdravnika ali nemudoma pojdite v ambulanto za nujno pomoč najbližje bolnišnice.
200 hard capsules
200 trdih kapsul
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities.
Ne vozite, ne upravljajte z zapletenimi stroji in ne sodelujte pri drugih potencialno nevarnih dejavnostih, dokler ne veste, ali to zdravilo poslabša vašo zmožnost za takšne dejavnosti.
No specific pharmacodynamic interaction studies were conducted in elderly volunteers.
Specifičnih raziskav farmakodinamičnih interakcij pri starejših prostovoljcih ni bilo.
The efficacy and safety of pregabalin as adjunctive treatment for epilepsy in paediatric patients below the age of 12 and adolescents has not been established.
Varnost in učinkovitost pregabalina kot dodatnega zdravljenja epilepsije pri pediatričnih bolnikih, mlajših od 12 let, in pri mladostnikih nista dokazani.
In rare occasions, cases of coma have been reported.
Redko so poročali o primerih kome.
Multiple dose pharmacokinetics are predictable from single-dose data.
Farmakokinetiko po več odmerkih je mogoče napovedati iz podatkov za posamičen odmerek.
• Feeling drunk, abnormal style of walking
• občutek pijanosti, nenormalna hoja
Other medicines and Pregabalin Mylan Pharma Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Druga zdravila in zdravilo Pregabalin Mylan Pharma Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
There have also been post-marketing reports of loss of consciousness, confusion and mental impairment.
V obdobju trženja so poročali tudi o izgubi zavesti, zmedenosti in poslabšanju mentalnih sposobnosti.
Ophthalmologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials.
Oftalmološke preiskave (vključno z določanjem ostrine vida, formalnim določanjem vidnega polja in pregledom očesnega ozadja pri razširjeni zenici) so v nadzorovanih kliničnih preskušanjih opravili pri več kot 3.600 bolnikih.
In conventional safety pharmacology studies in animals, pregabalin was well-tolerated at clinically relevant doses.
V običajnih raziskavah farmakološke varnosti pri živalih so le-te pregabalin v klinično pomembnih odmerkih dobro prenašale.
The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.
Na računa N-metiliranega derivata pregabalina, ki je glavni presnovek pregabalina v urinu, je šlo 0,9 % odmerka.
Total pregabalin daily dose *
tni dnevni odmerek pregabalina*
• Vertigo, problems with balance, fall
• vrtoglavica, težave z ravnotežjem, padec
• Pregabalin Mylan Pharma may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary.
• Uporaba zdravila Pregabalin Mylan Pharma lahko povzroči zamegljenost ali izgubo vida ali druge spremembe vida, med katerimi so mnoge začasne.
Pregabalin Mylan Pharma and certain other medicines may influence each other (interaction).
Zdravilo Pregabalin Mylan Pharma in določena druga zdravila imajo lahko medsebojno delovanje (interakcije).
PHARMACEUTICAL FORM AND CONTENTS Hard capsule.
FARMACEVTSKA OBLIKA IN VSEBINA trda kapsula
• Blurred vision, double vision
• zamegljen vid, dvojni vid
• Some patients with diabetes who gain weight while taking pregabalin may need an alteration in their diabetic medicines.
• Nekateri bolniki z diabetesom, ki so se med jemanjem pregabalina zredili, lahko potrebujejo zamenjavo diabetičnih zdravil.
Pregabalin binds to an auxiliary subunit (α2- δ protein) of voltage-gated calcium channels in the central nervous system.
Pregabalin se veže na pomožno podenoto (beljakovino α2- δ) napetostno odvisnih kalcijevih kanalčkov v osrednjem živčevju.
The safety and efficacy of Pregabalin Mylan Pharma in children below the age of 12 years and in adolescents (12-17 years of age) have not been established.
Varnost in učinkovitost zdravila Pregabalin Mylan Pharma pri otrocih, starih do 12 let, in pri mladostnikih (12-17 let) nista bili dokazani.
Very common: may affect more than 1 in 10 people • Dizziness, drowsiness, headache
Zelo pogosti: pojavijo se lahko pri najmanj 1 od 10 bolnikov • omotica, zaspanost, glavobol
The non-genotoxic mechanism of pregabalin-induced tumour formation in mice involves platelet changes and associated endothelial cell proliferation.
Negenotoksični mehanizem formacije tumorjev, inducirane s pregabalinom, pri miših vključuje spremembe trombocitov in s tem povezano proliferacijo endotelijskih celic.
Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.
Bolnikom je treba svetovati, naj ne vozijo, ne upravljajo zapletenh strojev in ne sodelujejo pri drugih potencialno nevarnih dejavnostih, dokler ni znano, kako to zdravilo vpliva na njihovo zmožnost za takšne dejavnosti.
Tell your doctor if you have a history of any serious medical conditions, including liver or kidney disease.
Zdravniku povejte, če ste v preteklosti imeli kakšne hujše zdravstvene težave, vključno z boleznijo jeter ali ledvic.
Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours).
Hemodializa učinkovito odstrani pregabalin iz plazme (50 % zdravila v 4 urah).
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription.
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept.
For three times a day take Pregabalin Mylan Pharma once in the morning, once in the afternoon and once in the evening, at about the same time each day.
Pregabalin Mylan Pharma dvakrat na dan, ga vzemite enkrat zjutraj in enkrat zvečer, in sicer vsak dan ob približno istem času.
Pregabalin oral bioavailability is estimated to be ≥ 90% and is independent of dose.
Ocenjena biološka uporabnost pregabalina po peroralni uporabi je ≥ 90 % in ni odvisna od odmerka.
In addition, pregabalin is effectively removed from plasma by haemodialysis (following a 4 hour haemodialysis treatment plasma pregabalin concentrations are reduced by approximately 50%).
Poleg tega hemodializa učinkovito odstrani pregabalin iz plazme (po 4-urni hemodializi se koncentracija pregabalina v plazmi zmanjša za približno 50 %).
BID = Two divided doses * Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose + Supplementary dose is a single additional dose
2-krat/dan = dva deljena odmerka * Celotni dnevni odmerek (mg/dan) je treba razdeliti, kot navaja odmerna shema, da dobimo mg/odmerek.
Adverse effects on male reproductive organs and sperm parameters were reversible and occurred only at exposures sufficiently in excess of therapeutic exposure or were associated with spontaneous degenerative processes in male reproductive organs in the rat.
Neželeni učinki na moške spolne organe in na lastnosti sperme so bili reverzibilni in so se pojavili samo pri izpostavljenosti, ki je bila v zadostni meri večja od terapevtske izpostavljenosti ali pa so bili povezani s spontanim degenerativnim procesom v spolnih organih pri podganjih samcih.
Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy receiving anti-epileptic drugs and patients with chronic pain.
Farmakokinetika pregabalina v stanju dinamičnega ravnovesja je podobna pri zdravih prostovoljcih, bolnikih z epilepsijo, ki dobivajo antiepileptična zdravila, in bolnikih s kroničnimi bolečinami.
• Decrease in white blood cell count
• zmanjšanje števila belih krvničk
Hypersensitivity Angioedema, allergic reaction
Redki preobčutljivost angioedem, alergična reakcija
No specific pharmacokinetic studies were carried out in patients with impaired liver function.
Specifičnih farmakokinetičnih raziskav pri bolnikih z okvarjenim delovanjem jeter ni bilo.
Pregabalin clearance is directly proportional to creatinine clearance.
Očistek pregabalina je neposredno sorazmeren očistku kreatinina.
The pregabalin clinical programme involved over 8900 patients exposed to pregabalin, of whom over 5600 were in double-blind placebo controlled trials.
Klinični program pregabalina je zajel prek 8.900 bolnikov, izpostavljenih temu zdravilu; 5.600 od teh je bilo vključenih v dvojno slepa, s placebom nadzorovana preskušanja.
The symptoms of GAD are prolonged excessive anxiety and worry that are difficult to control.
Simptoma te bolezni sta dolgotrajna in pretirano izražena tesnobnost in zaskrbljenost, ki ju bolnik le težko obvladuje.
Additional reactions reported from post-marketing experience are included in italics in the list below.
Dodatni neželeni učinki, o katerih so poročali v obdobju trženja, so v spodnji preglednici navedeni v ležeči pisavi.
This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age.
Zmanjšanje peroralnega očistka pregabalina je skladno z zmanjšanjem očistka kreatinina, ki je povezan z naraščajočo starostjo.
Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.
Zato plazemskih koncentracij pregabalina ni potrebno rutinsko nadzorovati.
The degree of dizziness, sleepiness and decreased concentration may be increased if Pregabalin Mylan Pharma is taken together with medicinal products containing:
Omotica, zaspanost ali zmanjšanje sposobnosti koncentracije se lahko stopnjujejo, če zdravilo Pregabalin Mylan Pharma vzamemo skupaj z zdravili, ki vsebujejo:
Capsules shell Iron oxide yellow (E172) Titanium dioxide (E171) Erythrosine (E127) Gelatin
Ovojnica kapsule rumeni železov oksid (E172) titanov dioksid (E171) eritrozin (E127) želatina natrijev lavrilsulfat
Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats.
Dokazano je, da pregabalin pri podganah prehaja skozi placento in je prisoten v mleku doječih podgan.
These symptoms may occur more commonly or severely if you have been taking Pregabalin Mylan Pharma for a longer period of time.
Ti znaki se lahko pojavljajo bolj pogosto in z večjo izrazitostjo, če ste zdravilo Pregabalin Mylan Pharma jemali daljši čas.
Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin misuse, abuse or dependence (development of tolerance, dose escalation, drug-seeking behaviour have been reported).
Pri bolnikih z anamnezo zlorabe prepovedanih snovi je potrebna previdnost in jih je potrebno nadzirati glede možnih simptomov nepravilne uporabe, zlorabe ali odvisnosti od pregabalina (poročali so o razvoju tolerance, povečevanju odmerka in povpraševanju po zdravilu).
At therapeutic exposures, there was evidence of CNS clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight gain suppression).
Pri izpostavljenosti terapevtskim odmerkom so bili opaženi klinični znaki prekomernega delovanja osrednjega živčnega sistema in bruksizma ter nekatere spremembe v rasti (prehodna supresija povečanja telesne mase).
Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may precipitate encephalopathy.
Poročali so o primerih encefalopatije, predvsem pri bolnikih z osnovnimi stanji, ki lahko izzovejo encefalopatijo.
The pharmacokinetics of 150 mg pregabalin given every 12 hours (300 mg daily dose) was evaluated in 10 lactating women who were at least 12 weeks postpartum.
Farmakokinetiko 150 mg pregabalina, z odmerjanjem na 12 ur (300 mg dnevno), so preučevali pri 10 doječih materah, pri katerih je od poroda minilo najmanj 12 tednov.
In vivo studies and population pharmacokinetic analysis Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol.
Raziskave in vivo in analiza populacijske farmakokinetike Skladno s tem v raziskavah in vivo niso ugotovili klinično pomembnih farmakokinetičnih interakcij med pregabalinom in fenitoinom, karbamazepinom, valprojsko kislino, lamotriginom, gabapentinom, lorazepamom, oksikodonom ali etanolom.
In prenatal/postnatal toxicity studies, pregabalin induced offspring developmental toxicity in rats at exposures >2 times the maximum recommended human exposure.
V raziskavah prednatalne/ponatalne toksičnosti je pregabalin povzročil razvojno toksičnost za potomstvo podgan pri izpostavljenostih, ki so bile > 2-krat večje od največje priporočene izpostavljenosti pri človeku.
Maximum dose (mg/day)
največji odmerek (mg/dan)
The other ingredients are: hydroxylpropylcellulose, maize starch, talc, gelatin, titanium dioxide (E171), sodium laurilsulfate, black ink (which contains shellac, black iron oxide (E172), macrogol, potassium hydroxide and concentrated ammonia solution), yellow iron oxide (E172) and erythrosine (E127).
Druge sestavine zdravila so: hidroksipropilceluloza, koruzni škrob, smukec, želatina, titanov dioksid (E171), natrijev lavrilsulfat, črno črnilo (ki vsebuje šelak, črni železov oksid (E172), makrogol, kalijev hidroksid in koncentrirano raztopino amonijaka), rumeni železov oksid (E172) in eritrozin (E127).
In the post-marketing experience, visual adverse reactions have also been reported, including loss of vision, visual blurring or other changes of visual acuity, many of which were transient.
V obdobju trženja so poročali tudi o neželenih učinkih na vid; vključno z izgubo vida, zamegljenostjo vida ali drugimi spremembami ostrine vida, med katerimi so bile mnoge prehodnega značaja.
Pregnancy There are no adequate data from the use of pregabalin in pregnant women.
Nosečnost O uporabi pregabalina pri nosečnicah ni zadostnih podatkov.
Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of pregabalin.
Klinična preskušanja kažejo, da spol nima klinično pomembnega vpliva na koncentracijo pregabalina v plazmi.
Generalised Anxiety Disorder
Generalizirana anksiozna motnja